Zobrazeno 1 - 10
of 606
pro vyhledávání: '"Giancarlo Pruneri"'
Autor:
Serena Di Cosimo, Sara Pizzamiglio, Chiara Maura Ciniselli, Valeria Duroni, Vera Cappelletti, Loris De Cecco, Cinzia De Marco, Marco Silvestri, Maria Carmen De Santis, Andrea Vingiani, Biagio Paolini, Rosaria Orlandi, Marilena Valeria Iorio, Giancarlo Pruneri, Paolo Verderio
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene amplification. However, in daily practice, the accuracy of IHC is comp
Externí odkaz:
https://doaj.org/article/d7df224a01ee4e5988733bfc39acbfb0
Autor:
Marius Bartels, Benoist Chibaudel, Rodrigo Dienstmann, Janne Lehtiö, Alberta Piccolo, Olivier Michielin, Grainne O’Kane, Giancarlo Pruneri
Publikováno v:
Cancers, Vol 16, Iss 16, p 2888 (2024)
The increasing volume of information for cancer care, and the evolution of molecularly guided therapies, have increased the need for molecular tumor boards (MTBs), which can integrate such data into personalized treatment plans to improve patient out
Externí odkaz:
https://doaj.org/article/5a2bc37483314bd7a579074d2e489278
Autor:
Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Roberta Mortarini, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Rossella Tufano, Davide Bedognetti, Andrea Anichini, Michele Maio, Michele Ceccarelli
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract Association with hypomethylating agents is a promising strategy to improve the efficacy of immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation trial in patients with advanced melanoma of the hypomethylati
Externí odkaz:
https://doaj.org/article/05375b66e651420298a4c3d815f3dee9
Autor:
Jacopo Azzollini, Luca Agnelli, Elena Conca, Tommaso Torelli, Adele Busico, Iolanda Capone, Marta Angelini, Elena Tamborini, Federica Perrone, Andrea Vingiani, Daniele Lorenzini, Bernard Peissel, Giancarlo Pruneri, Siranoush Manoukian
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Tumour DNA sequencing is essential for precision medicine since it guides therapeutic decisions but also fosters the identification of patients who may benefit from germline testing. Notwithstanding, the tumour-to-germline testing workflow p
Externí odkaz:
https://doaj.org/article/1201518e80a843888ac0f10a86f7d812
Autor:
Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2− aBC). Objectives: While CDK4/6i
Externí odkaz:
https://doaj.org/article/997ec44c91b244349cd2462f6a583683
Autor:
Marco Silvestri, Trung Nghia Vu, Federico Nichetti, Monica Niger, Serena Di Cosimo, Filippo De Braud, Giancarlo Pruneri, Yudi Pawitan, Stefano Calza, Vera Cappelletti
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 10156-10168 (2023)
Abstract Background Cholangiocarcinoma (CC) is a rare and aggressive disease with limited therapeutic options and a poor prognosis. All available public records of cohorts reporting transcriptomic data on intrahepatic cholangiocarcinoma (ICC) and ext
Externí odkaz:
https://doaj.org/article/e6283a90f55d4b91b0337654fc69c14a
Autor:
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 pat
Externí odkaz:
https://doaj.org/article/1b8f8d9603654e7590deb24e3d8b863d
Autor:
Emanuela Minna, Andrea Devecchi, Federico Pistore, Biagio Paolini, Giuseppe Mauro, Donata Alda Penso, Sonia Pagliardini, Adele Busico, Giancarlo Pruneri, Loris De Cecco, Maria Grazia Borrello, Marialuisa Sensi, Angela Greco
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
BackgroundPapillary thyroid carcinoma (PTC) is the most common type of thyroid cancer (TC). Several genomic and transcriptomic studies explored the molecular landscape of follicular cell-derived TCs, and BRAFV600E, RAS mutations, and gene fusions are
Externí odkaz:
https://doaj.org/article/a2ba787322b94a97926f10f8def11ee5
Autor:
Jessica Burroughs Garcia, Paola Storti, Nicolas Thomas Iannozzi, Valentina Marchica, Luca Agnelli, Denise Toscani, Valentina Franceschi, Giannalisa Todaro, Gabriella Sammarelli, Laura Notarfranchi, Matteo Scita, Benedetta Dalla Palma, Vincenzo Raimondi, Oxana Lungu, Giancarlo Pruneri, Gaetano Donofrio, Nicola Giuliani
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Externí odkaz:
https://doaj.org/article/776334aa5c954de38fa684c14dafd845
Autor:
Giancarlo Pruneri, Daniele Lorenzini, Mauro G. Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C. Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-4 (2023)
Multigenic tests represent an essential tool for the selection of adjuvant therapy in estrogen-positive/HER2-negative (ER + /HER2-) early breast cancer (BC). The workflow of these tests, either if they are externalized or carried out in-house, genera
Externí odkaz:
https://doaj.org/article/69dd406149ad42729238c4c9f88b56fd